{name}
{subtitle}
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~35 mi. (Grålum, Norway, +144 more cities)
facility
Sykehuset Østfold HF Kalnes ( Site 2003)
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
city
~35 mi. (Grålum, Norway, +158 more cities)
facility
Sykehuset Oestfold ( Site 1107)
drug
olaparib, +4 more drugs
drug type
chemotherapy, +3 more types
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
city
~64 mi. (Løren, Norway, +130 more cities)
facility
Akershus University Hospital ( Site 0553)
drug
BCG solution, +1 more drug